JP2021529805A5 - - Google Patents
Info
- Publication number
- JP2021529805A5 JP2021529805A5 JP2021500178A JP2021500178A JP2021529805A5 JP 2021529805 A5 JP2021529805 A5 JP 2021529805A5 JP 2021500178 A JP2021500178 A JP 2021500178A JP 2021500178 A JP2021500178 A JP 2021500178A JP 2021529805 A5 JP2021529805 A5 JP 2021529805A5
- Authority
- JP
- Japan
- Prior art keywords
- ivosidenib
- powder
- ray diffraction
- diffraction pattern
- dsc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024131926A JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694596P | 2018-07-06 | 2018-07-06 | |
| US62/694,596 | 2018-07-06 | ||
| PCT/US2019/040257 WO2020010058A1 (en) | 2018-07-06 | 2019-07-02 | Ivosidenib forms and pharmaceutical compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131926A Division JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529805A JP2021529805A (ja) | 2021-11-04 |
| JP2021529805A5 true JP2021529805A5 (enExample) | 2022-07-12 |
| JP7621242B2 JP7621242B2 (ja) | 2025-01-24 |
Family
ID=69059942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500178A Active JP7621242B2 (ja) | 2018-07-06 | 2019-07-02 | イボシデニブ形態および医薬組成物 |
| JP2024131926A Withdrawn JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131926A Withdrawn JP2024150784A (ja) | 2018-07-06 | 2024-08-08 | イボシデニブ形態および医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12264148B2 (enExample) |
| EP (2) | EP3817744A4 (enExample) |
| JP (2) | JP7621242B2 (enExample) |
| KR (2) | KR102919157B1 (enExample) |
| CN (1) | CN112367995A (enExample) |
| AU (2) | AU2019299352B2 (enExample) |
| BR (1) | BR112021000156A2 (enExample) |
| CA (1) | CA3103498A1 (enExample) |
| EA (1) | EA202190217A1 (enExample) |
| IL (2) | IL315423B1 (enExample) |
| MA (1) | MA53099A (enExample) |
| MX (2) | MX2021000068A (enExample) |
| PH (1) | PH12021550017A1 (enExample) |
| SG (1) | SG11202012763TA (enExample) |
| TW (2) | TWI911130B (enExample) |
| UA (1) | UA129800C2 (enExample) |
| WO (1) | WO2020010058A1 (enExample) |
| ZA (1) | ZA202008034B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020327013B2 (en) | 2019-08-08 | 2026-03-26 | Les Laboratoires Servier | A method for preparing Ivosidenib and an intermediate thereof |
| GB201912411D0 (en) * | 2019-08-29 | 2019-10-16 | Johnson Matthey Plc | Crystalline forms of ivosidenib |
| AR133410A1 (es) | 2023-08-01 | 2025-09-24 | Servier Lab | Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| RU2013144975A (ru) * | 2011-04-08 | 2015-05-20 | Пфайзер Инк. | Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| AR092439A1 (es) * | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
| MA39725B1 (fr) * | 2014-03-14 | 2021-09-30 | Les Laboratoires Servier Sas | Compositions pharmaceutiques de composés thérapeutiquement actifs |
| NZ723859A (en) * | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| KR102699521B1 (ko) * | 2015-10-15 | 2024-08-26 | 르 라보레또레 쎄르비에르 | 악성 종양의 치료를 위한 조합물 요법 |
| MA43640A (fr) * | 2016-02-26 | 2018-11-28 | Agios Pharmaceuticals Inc | Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides |
| US11066390B2 (en) | 2017-11-27 | 2021-07-20 | Assia Chemical Industries Ltd. | Solid state forms of Ivosidenib |
-
2019
- 2019-07-02 EA EA202190217A patent/EA202190217A1/ru unknown
- 2019-07-02 CN CN201980045552.5A patent/CN112367995A/zh active Pending
- 2019-07-02 EP EP19829932.3A patent/EP3817744A4/en not_active Withdrawn
- 2019-07-02 IL IL315423A patent/IL315423B1/en unknown
- 2019-07-02 JP JP2021500178A patent/JP7621242B2/ja active Active
- 2019-07-02 KR KR1020217000885A patent/KR102919157B1/ko active Active
- 2019-07-02 UA UAA202100436A patent/UA129800C2/uk unknown
- 2019-07-02 CA CA3103498A patent/CA3103498A1/en active Pending
- 2019-07-02 BR BR112021000156-5A patent/BR112021000156A2/pt unknown
- 2019-07-02 EP EP25187804.7A patent/EP4603147A3/en active Pending
- 2019-07-02 MX MX2021000068A patent/MX2021000068A/es unknown
- 2019-07-02 US US17/258,102 patent/US12264148B2/en active Active
- 2019-07-02 SG SG11202012763TA patent/SG11202012763TA/en unknown
- 2019-07-02 WO PCT/US2019/040257 patent/WO2020010058A1/en not_active Ceased
- 2019-07-02 AU AU2019299352A patent/AU2019299352B2/en active Active
- 2019-07-02 KR KR1020257038241A patent/KR20250164882A/ko active Pending
- 2019-07-02 MA MA053099A patent/MA53099A/fr unknown
- 2019-07-05 TW TW114126745A patent/TWI911130B/zh active
- 2019-07-05 TW TW108123796A patent/TWI902665B/zh active
-
2020
- 2020-12-22 ZA ZA2020/08034A patent/ZA202008034B/en unknown
- 2020-12-30 IL IL279877A patent/IL279877A/en unknown
-
2021
- 2021-01-04 PH PH12021550017A patent/PH12021550017A1/en unknown
- 2021-01-06 MX MX2023011687A patent/MX2023011687A/es unknown
-
2024
- 2024-08-08 JP JP2024131926A patent/JP2024150784A/ja not_active Withdrawn
-
2025
- 2025-05-23 AU AU2025203835A patent/AU2025203835A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI788702B (zh) | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 | |
| JP5546717B2 (ja) | アリピプラゾール結晶質形態を調製する方法 | |
| JP6634368B2 (ja) | 複素環式化合物及びそれらの使用 | |
| JP2021529805A5 (enExample) | ||
| US12365680B2 (en) | Polymorphs of the hydrochloride salt of linaprazan glurate | |
| JP2024537795A5 (enExample) | ||
| JP2022532404A (ja) | Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 | |
| WO2004000317A1 (en) | Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride | |
| WO2016125190A2 (en) | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof | |
| KR20260042158A (ko) | 메닌 억제제를 포함하는 약학적 조성물 | |
| US20130225830A1 (en) | Polymorphs of febuxostat | |
| TW201311240A (zh) | 非晶形哌啶基化合物之生物可利用組合物 | |
| JP2026503095A (ja) | リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）の臭化水素酸塩の多形 | |
| JP2013501751A (ja) | 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター | |
| JP2024542115A (ja) | リナプラザングルレートのメシラート塩の多形体 | |
| JP5530369B2 (ja) | 新規な結晶形 | |
| JP2007269628A (ja) | 医薬化合物の結晶 | |
| JP6393310B2 (ja) | ５−クロロ−チオフェン−２−カルボン酸［（ｓ）−２−［メチル−３−（２−オキソ−ピロリジン−１−イル）−ベンゼンスルホニルアミノ］−３−（４−メチル−ピペラジン−１−イル）−３−オキソ−プロプリル］アミドの酒石酸塩 | |
| JP2019530719A (ja) | ４−（２−（（１ｒ，２ｒ）−２−ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール−６−イルオキシ）−ｎ−メチルピコリンアミドの結晶形 | |
| TWI922665B (zh) | (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式 | |
| JP2026503096A (ja) | リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）のマレイン酸塩の多形 | |
| HK40092799A (zh) | Pn6047盐酸盐的多晶型物 | |
| JP2023115525A (ja) | ロスバスタチンアリルエステルの結晶形態 | |
| JP2004168772A (ja) | 受容体調節剤 | |
| CA3079142A1 (en) | Amorphous form of pimavanserin hemitartrate |